TipRanks

Notifications

Tag: MRNS

Total 204 Posts

Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cellectar Biosciences (CLRBResearch Report), MiMedx Group (MDXGResearch Report) and Marinus (MRNSResearch Report).

Cellectar Biosciences (CLRB)

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Cellectar Biosciences, with a price target of $12.00. The company’s shares closed last Wednesday at $3.64.

According to TipRanks.com, Jones is a 4-star analyst with an average return of 18.7% and a 36.7% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Fusion Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Cellectar Biosciences is a Strong Buy with an average price target of $13.00.

See Insiders’ Hot Stocks on TipRanks >>

MiMedx Group (MDXG)

Lake Street analyst Brooks O’Neil maintained a Buy rating on MiMedx Group today and set a price target of $12.00. The company’s shares closed last Wednesday at $7.61.

According to TipRanks.com, O’Neil is a 3-star analyst with an average return of 1.8% and a 46.3% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, InfuSystem Holdings, Inc., and Tandem Diabetes Care.

MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.25, implying a 60.3% upside from current levels. In a report issued on March 20, Craig-Hallum also maintained a Buy rating on the stock.

Marinus (MRNS)

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Marinus, with a price target of $9.00. The company’s shares closed last Wednesday at $8.85.

According to TipRanks.com, Olson is a 5-star analyst with an average return of 19.7% and a 45.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crispr Therapeutics AG, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $19.78.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CLRB:

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), Arcutis Biotherapeutics (ARQT) and Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNSResearch Report), Arcutis Biotherapeutics (ARQTResearch Report) and Axsome Therapeutics (AXSMResearch Report) with bullish sentiments.

Marinus (MRNS)

In a report issued on March 24, Marc Goodman from Leerink Partners maintained a Buy rating on Marinus, with a price target of $20.00. The company’s shares closed last Tuesday at $8.79.

According to TipRanks.com, Goodman is a 4-star analyst with an average return of 4.8% and a 44.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $19.78 average price target, an 111.8% upside from current levels. In a report issued on March 24, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

Arcutis Biotherapeutics (ARQT)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics on March 22 and set a price target of $17.00. The company’s shares closed last Tuesday at $9.27.

According to TipRanks.com, Ear is a 4-star analyst with an average return of 8.7% and a 44.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Relmada Therapeutics, and Sarepta Therapeutics.

Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.40.

Axsome Therapeutics (AXSM)

In a report issued on March 25, Graig Suvannavejh from Mizuho Securities assigned a Buy rating to Axsome Therapeutics, with a price target of $108.00. The company’s shares closed last Tuesday at $76.72.

According to TipRanks.com, Suvannavejh is ranked 0 out of 5 stars with an average return of -6.8% and a 42.8% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Harmony Biosciences Holdings, and Amylyx Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $125.33 average price target, a 59.9% upside from current levels. In a report issued on March 18, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $108.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRNS:

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Precigen (PGENResearch Report), Cronos Group (CRONResearch Report) and Marinus (MRNSResearch Report).

Precigen (PGEN)

J.P. Morgan analyst Brian Cheng downgraded Precigen to Sell today. The company’s shares closed last Monday at $1.41.

According to TipRanks.com, Cheng is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.1% and a 30.1% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Intellia Therapeutics, and Allogene Therapeutics.

Currently, the analyst consensus on Precigen is a Moderate Buy with an average price target of $10.00.

See the top stocks recommended by analysts >>

Cronos Group (CRON)

Jefferies analyst Owen Bennett maintained a Hold rating on Cronos Group yesterday and set a price target of C$3.23. The company’s shares closed last Monday at $2.49.

According to TipRanks.com, Bennett ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.7% and a 37.9% success rate. Bennett covers the Healthcare sector, focusing on stocks such as Cannabist Company Holdings, OrganiGram Holdings, and Aurora Cannabis.

Currently, the analyst consensus on Cronos Group is a Moderate Sell with an average price target of $2.15.

Marinus (MRNS)

Jefferies analyst Andrew Tsai maintained a Buy rating on Marinus on March 24 and set a price target of $22.00. The company’s shares closed last Monday at $8.93.

According to TipRanks.com, Tsai is ranked #2238 out of 8761 analysts.

Marinus has an analyst consensus of Strong Buy, with a price target consensus of $19.78, which is a 124.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $28.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PGEN: